Ignite Creation Date:
2024-05-06 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04690595
Status:
RECRUITING
Last Update Posted:
2024-05-10
First Post:
2020-12-24
Brief Title:
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
Sponsor:
PeproMene Bio Inc
Organization:
PeproMene Bio Inc
Study Overview
Official Title:
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Detailed Description:
This phase I trial evaluates the side effects and best dose of BAFFR-CAR T cells in treating patients with B-cell Acute Lymphoblastic Leukemia that has come back recurrent or does not respond to treatment refractory T cells are infection fighting blood cells that can kill cancer cells The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize BAFFR a protein on the surface of cancer cells These BAFFR-specific T cells may help the bodys immune system identify and kill BAFFR cancer cells
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None